Skip to main content
    P

    Procept Biorobotics Corp (PRCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $23.54
    -0.26 (-1.09%)

    Market Cap: $1.37B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Procept Biorobotics Corp (PRCT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Procept Biorobotics reported revenue of $308.05M for the fiscal year ended Dec 31, 2025, up 37.2% from the year before. That year, net income was -$95.57M with a net margin of -31.0%, operating cash flow was -$48.98M and free cash flow was -$58.34M. The quarter ended Sep 30, 2026 had revenue of $98.29M and net income of -$26.52M.

    Revenue and Margins

    The operating margin was -33.7% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $6.17M, a compound annual rate of 91.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$308.05M+37.2%63.7%-33.7%-31.0%
    Dec 2024$224.50M+64.8%61.1%-43.0%-40.7%
    Dec 2023$136.19M+81.6%52.2%-80.2%-77.8%
    Dec 2022$75.01M+117.6%49.4%-107.6%-116.2%
    Dec 2021$34.47M+346.7%46.0%-157.1%-173.6%
    Dec 2020$7.72M+25.1%-16.3%-619.4%-687.0%
    Dec 2019$6.17MN/A-30.6%-705.9%-680.4%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$308.05M$224.50M$136.19M$75.01M$34.47M$7.72M$6.17M
    Cost of revenue$111.83M$87.40M$65.14M$37.93M$18.61M$8.97M$8.05M
    Gross profit$196.23M$137.10M$71.05M$37.09M$15.87M-$1.25M-$1.89M
    Research and development$71.28M$62.30M$48.45M$28.98M$18.99M$16.27M$13.15M
    Operating income-$103.86M-$96.61M-$109.17M-$80.72M-$54.16M-$47.80M-$43.55M
    Net income-$95.57M-$91.41M-$105.90M-$87.15M-$59.85M-$53.02M-$41.98M
    EBITDA-$85.41M-$81.63M-$98.02M-$75.87M-$50.72M-$44.90M-$39.76M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$98.29M$94.50M$83.13M$76.38M$83.33M$79.18M$69.16M$68.24M$58.37M$53.35M$44.54M$43.58M
    Gross profit$65.15M$62.38M$53.95M$46.31M$54.01M$51.75M$44.16M$43.67M$36.91M$31.48M$25.03M$21.25M
    Operating income-$27.38M-$27.39M-$32.61M-$31.04M-$23.19M-$22.19M-$27.44M-$19.71M-$22.43M-$26.83M-$27.65M-$29.56M
    Net income-$26.52M-$26.86M-$31.64M-$29.85M-$21.41M-$19.58M-$24.74M-$18.86M-$20.97M-$25.63M-$25.96M-$27.51M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded long-term debt of $51.62M by $234.89M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$508.08M$534.02M$404.72M$309.33M$337.02M$125.97M$61.99M
    Current assets$450.38M$481.84M$350.57M$272.63M$326.17M$110.26M$50.36M
    Cash and equivalents$286.50M$333.73M$257.22M$221.86M$304.32M$100.13M$42.02M
    Total liabilities$142.21M$131.80M$123.97M$112.26M$69.93M$65.01M$32.76M
    Short-term debtN/A$1.91M$1.68M$2.13M$2.10M$4.55M$3.07M
    Long-term debt$51.62M$51.47M$51.34M$51.21M$50.00M$44.41M$23.22M
    Shareholder equity$365.87M$402.22M$280.75M$197.07M$267.09M-$182.89M$29.23M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$473.76M$479.35M$487.06M$508.08M$511.54M$513.05M$519.38M$534.02M$374.14M$374.35M$382.90M$404.72M
    Total liabilities$144.85M$139.28M$139.40M$142.21M$131.26M$127.26M$130.22M$131.80M$132.92M$122.57M$118.85M$123.97M
    Cash and equivalents$218.37M$227.91M$245.64M$286.50M$294.28M$302.72M$316.21M$333.73M$196.76M$214.09M$225.58M$257.22M
    Shareholder equity$328.91M$340.07M$347.67M$365.87M$380.28M$385.80M$389.16M$402.22M$241.22M$251.78M$264.05M$280.75M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$48.98M-$99.21M-$108.00M-$80.38M-$57.33M-$48.34M-$43.82M
    Capital expenditures$9.36M$4.41M$25.21M$2.65M$592.00K$233.00K$7.61M
    Free cash flow-$58.34M-$103.62M-$133.21M-$83.03M-$57.93M-$48.58M-$51.43M
    Investing cash flow-$9.36M-$4.41M-$25.21M-$2.65M-$592.00K-$233.00K$43.15M
    Financing cash flow$11.19M$180.13M$167.79M$3.61M$262.12M$106.77M$26.53M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$8.98M-$19.25M-$38.13M-$10.33M-$6.63M-$15.04M-$16.98M-$32.39M-$18.80M-$15.74M-$32.29M-$24.79M
    Capital expenditures$667.00K$2.95M$2.91M$1.85M$2.87M$2.80M$1.84M$1.17M$246.00K$1.04M$1.95M$8.71M
    Free cash flow-$9.65M-$22.20M-$41.04M-$12.18M-$9.50M-$17.84M-$18.82M-$33.56M-$19.05M-$16.78M-$34.23M-$33.51M
    Last 12 quarters

    Frequently Asked Questions About PRCT

    What is Procept Biorobotics' annual revenue?

    Procept Biorobotics reported revenue of $308.05M for the fiscal year ended Dec 31, 2025.

    How fast is Procept Biorobotics' revenue growing?

    Revenue was up 37.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 60.1%.

    Is Procept Biorobotics profitable?

    No. Procept Biorobotics reported net income of -$95.57M for the fiscal year ended Dec 31, 2025, with a net margin of -31.0%.

    How much free cash flow does PRCT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$48.98M minus capital expenditures of $9.36M produced free cash flow of -$58.34M.

    How much debt does Procept Biorobotics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $51.62M and cash and equivalents of $286.50M.